Skip Navigation

Rheumatology 2008 47(Supplement 3):iii13-iii15; doi:10.1093/rheumatology/ken152
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Doria, A.
Right arrow Articles by Salvarani, C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Doria, A.
Right arrow Articles by Salvarani, C.
Related Collections
Right arrow Vasculitis
Right arrow Pregnancy and Rheumatic Diseases
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Pre-pregnancy counselling of patients with vasculitis

A. Doria1, G. Bajocchi2, M. Tonon1 and C. Salvarani2

1Division of Rheumatology, Department of Medical and Surgical Sciences, University of Padova, Padova and 2Rheumatology Unit Arcispedale S. Maria Nuova, Reggio Emilia, Italy.

Correspondence to: A. Doria, Division of Rheumatology, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy. E-mail: adoria{at}unipd.it


  Abstract

The knowledge about the risk of pregnancy in vasculitides mostly derives from single case reports or at best from retrospective studies with all the caveats that these observations include. Primary systemic vasculitides are uncommon, encompassing a broad spectrum of severity, from mild to life-threatening manifestations and with different natural histories, from self-limiting to relapsing or chronic active disease. The treatments require a cautious use of immunosuppressants tailored to each specific condition. Furthermore, most of the cytotoxic drugs necessary to treat vasculitis act by modifying the cell cycle and cell differentiation, biological effects that are particularly hazardous for the foetus. In order to have an uncomplicated pregnancy, conception should be planned when the disease is inactive. Moreover, organ failure or damage, due to previous disease activity, must also be taken into account since it can lead to adverse obstetrical and fetal outcomes.

KEY WORDS: Risk, Pregnancy, Systemic vasculitis, Cytotoxic drugs

Submitted 14 March 2008; Accepted 27 March 2008


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
M. Cutolo, M. Matucci-Cerinic, M. Lockshin, and M. Ostensen
Introduction: new trends in pregnancy and rheumatic diseases
Rheumatology, June 1, 2008; 47(suppl_3): iii1 - iii1.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.